[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bladder-cancer-requiring-cystectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bladder-cancer-requiring-cystectomy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,80,116,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641796","phase-3-stent-x-a-randomized-trial-to-assess-stent-free-radical-cystectomy-100641796",false,"NCT07655284","STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy","STENT X Non-stent Genito-urinary Tract Reconstruction After Radical Cystectomy for Bladder Cancer - a Prospective, Randomized, Controlled and Multi Institutional Trial","Inclusion Criteria:\n\n* Adults (\\> 18 years old)\n* Muscle invasive bladder cancer or non-muscle invasive bladder cancer with indication of Radical Cystectomy\n* No concomitant surgeries like nephrectomies, colectomies or removal of other organs affected by the tumor (Except standard lymph node dissections as well as in men the prostate and seminal vesicles and in women the uterus, fallopian tubes, ovaries and vagina, that are considered part of the oncological radical cystectomy.)\n* Patients who have the capacity to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Simultaneous surgical procedures (except those specified in the inclusion criteria that are considered part of a routine radical cystectomy)\n* History of prior urinary diversion\n* Patients who decline to participate, lack understanding of the study's purpose, or are unable to provide informed consent\n* Cystectomy for other reasons than Bladder cancer\n* Previous radiation therapy in the pelvis for any reason\n* Extremely debilitated patients, malnourished individuals, or those undergoing palliative or hygienic cystectomy","ALL","18 Years",{"count":19,"type":20},190,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches.",[26,27],"Bladder Cancer Requiring Cystectomy","Ureteral Stents",[29,30,31],"bladder cancer","cystectomy","ureteral stents","NOT_YET_RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":20},"2026-09-01",{"date":40,"type":20},"2029-08-31",{"name":42,"class":43},"Brigham and Women's Hospital","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100603751","pilot-study-of-a-new-nerve-grafting-method-during-bladder-cancer-surgery-to-help-preserve-erections-100603751","NCT07140588","Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.","Pilot Study of Intraoperative Somatic-Autonomic Nerve Grafting Technique to Preserve Erectile Function in Patients With Bladder Cancer Undergoing Radical Cystectomy","NR-RC","Inclusion Criteria:\n\n* Patients undergoing standard of care radical cystectomy for bladder cancer\n* Patients must have preoperative erectile function with a baseline IIEF score of ≥17\n\nExclusion Criteria:\n\n* Patients with previous pelvic surgery\n* Patients with previous pelvic radiotherapy\n* Patients aged \\\u003C 18 years at diagnosis\n* Legally incapable patients\n* Patients who are unable to complete questionnaires and have no companion to help complete them\n* Patients undergoing a concomitant cancer surgery\n* Patients with pre-existing neurologic disease","MALE",{"count":55,"type":20},10,[57],"NA","This pilot study will evaluate the safety and 1-year erectile function recovery in 10 patients undergoing a novel Nerve Restoring Radical Cystectomy (NR-RC), which includes a genitofemoral nerve graft. Erectile function will be assessed using IIEF-5, SF-MPQ, and CEEF questionnaires at baseline and at multiple post-operative intervals (4 weeks, 3, 6, 12, and 18 months). Safety will be monitored through peri- and post-operative complications, and additional demographic and clinical data will be collected for analysis.",[26,60],"Erectile Dysfunction Following Radical Prostatectomy",[62,63,64,65,66,67,68,69,70],"Bladder cancer","Nerve grafting","The genitofemoral nerve","radical cystectomy","radical prostatectomy","Erectile function","International Index of Erectile Function-5","Short Form McGill Pain Questionnaire","Clinical Evolution of Erectile Function","2025-08-18",{"date":73,"type":36},"2025-08-24",{"date":75,"type":20},"2025-09",{"date":77,"type":20},"2029-02",{"name":79,"class":43},"Sir Mortimer B. Davis - Jewish General Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100598150","phase-3-treatment-expedition-with-mri-processing-and-optimization-for-muscle-invasive-bladder-cancer-100598150","NCT07067749","Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer","TEMPO-MIBC","Inclusion Criteria:\n\n* Clinical suspicion of muscle invasive bladder cancer at cystoscopy and pre-cystoscopy imaging\n\nExclusion Criteria:\n\n* Anticipated survival \\\u003C 3 months due to comorbidities\n* Pregnant patients\n* Breastfeeding patients\n* Previous chemotherapy within 6 weeks\n* Previous radiotherapy withing 6 weeks\n* Previous TURBt within 6 weeks\n* Severe renal impairment (eGFR \\\u003C 40 mL\u002Fmin\u002F1.73 m2)\n* non MRI-compatible metal implants\n* Claustrophobia\n* Denial of written consent to participate in the study",{"count":88,"type":20},92,[23],"The TEMPO-MIBC trial is a phase III, single-center, two-arm, randomized, controlled trial. Its primary objective is to evaluate the efficacy of a simplified diagnostic and treatment pathway for muscle-invasive bladder cancer (MIBC). This study investigates the role of multiparametric bladder MRI (mpMRI) in patients with biopsy proven cancer of the bladder with clinical features of detrusor muscle invasion. In the experimental arm, enrolled patients will receive a bladder mpMRI, if this exam will confirm the high suspicion of muscle invasion a conventional endoscopic transurethral resection of bladder tumour (TURBt) for staging purposes will be foregone and patients will immediately access the next step of their clinical management. Experimental arm outcomes will be compared to a control arm in which all enrolled patients will be receiving TURBt as part of the standard management of bladder cancer. The aim of this study is demonstrating a significant reduction of the time needed to offer patients the definitive treatment for their disease, possibly ensuring better long-term oncological outcomes.\n\nA blood sample will be collected from each patient enrolled in the study at pre-planned time points to measure the levels of circulating tumour (ctDNA), a primer will be built from bladder cancer biopsies performed at enrolment. ctDNA has been shown to be a proxy measure of tumour burden and residual molecular disease after treatment. The ctDNA levels in the experimental arm will be compared to those of the control arm to investigate wether foregoing endoscopic resection of the tumour and reducing time to definitive cancer treatment might be associated to lower ctDNA levels.",[92,26,93,94,95],"Bladder (Urothelial, Transitional Cell) Cancer","Bladder Carcinoma","Bladder Neoplasm","Muscle Invasive Bladder Cancer (MIBC)",[97,98,99,100,101,102,103,104],"Muscle Invasive Bladder Cancer","VI-RADS","Bladder Magnetic Resonance Imaging","Cystectomy","TURBT","treatment expedition","cancer management optimisation","circulating tumour DNA","RECRUITING","2025-07-19",{"date":108,"type":36},"2025-07-24",{"date":110,"type":20},"2025-08-15",{"date":112,"type":20},"2030-08-15",{"name":114,"class":43},"University of Rome Tor Vergata",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":115},"100561844","a-feasibility-randomized-trial-evaluating-early-vs-late-stent-removal-following-radical-cystectomy-and-ileal-conduit-formation-for-bladder-cancer-100561844","NCT06595446","A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer","A Feasibility Randomized Controlled Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer","STENT-OPT","Inclusion Criteria:\n\n* Adult patients (18 years or older) undergoing radical cystectomy and ileal conduit formation for bladder cancer\n* Able to give informed written consent to participate.\n\nExclusion Criteria:\n\n* Treatment without curative intent (cT4b, salvage or palliative cystectomies);\n* Patients undergoing alternative forms of urinary diversion (e.g. continent cutaneous urinary diversion or orthotopic neobladder formation)\n* Patients previously received abdominal\u002Fpelvic radiotherapy\n* Patients with concomitant upper urinary tract cancer",{"count":125,"type":20},60,[57],"Bladder cancer is the 4th most common cancer in men and 5th most common type of cancer in Canada. Urothelial cancer accounts for approximately 90% of malignancies. At diagnosis, over 75% of cases are classified as non-muscle invasive (NMIBC), and with appropriate treatment, the majority of these patients achieve positive outcomes. The progression rate of NMIBC to Muscle-invasive bladder cancer (MIBC) varies between 5-50% at 5 years dependent on histopathological features such as grade, stage, presence of CIS and age (Carcinoma in Situ). The optimal treatment of MIBC (T2-T4N0M0) consists of neoadjuvant cisplatin-based chemotherapy followed by Radical cystectomy and urinary diversion (RCUD). In the last couple of decades, RCUD has also gained attention for treating patients with high-risk non-muscle invasive bladder cancer. Despite advancements in surgical techniques and the rise of minimally invasive alternatives, complications after surgery remain frequent, with morbidity rates of approximately 50%.\n\nSeveral uncertainties persist in surgical practice, including the role of perioperative ureteric stenting during RCUD. Perioperative ureteric stenting is intended to minimize urinary leakage from the newly created uretero-enteric anastomosis and to prevent early obstruction caused by anastomotic swelling. However, stenting may increase the risk of urinary tract infections (UTIs) and necessitate additional follow-up for stent removal. Peng et al. conducted the most recent systematic review in 2021, demonstrating that ureteral stents in RCUD were linked to higher rates of anastomotic strictures. Their review did not provide evidence that these stents were more effective than not using stents in preventing post-diversion urinary leakage. The review underscored the scarcity of prospective randomized controlled trials examining the safety and effectiveness of stenting in this context. The sole prospective (non-randomized) study assessing stent dwell \u002F retention time after RCUD demonstrated early stent removal (2 weeks) had decreased 90-day readmissions and UTIs.\n\nTherefore, the investigators aimed to determine the feasibility of conducting a definitive randomized trial to evaluate patients undergoing radical cystectomy and ileal conduit formation to receive either early stent removal (5-7 days) or late stent removal (4-6 weeks).",[26,129,130],"Ileal Conduit","Urinary Diversion",[62,132,133,134,135],"Radical cystectomy","Stent dwell time","Complications","Ileal conduit","2025-04-01",{"date":138,"type":36},"2025-04-04",{"date":140,"type":36},"2024-11-12",{"date":142,"type":20},"2026-10-01",{"name":144,"class":43},"Western University, Canada",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":5},"100570588","phase-4-clinical-trial-testing-whether-targeted-antibiotic-prophylaxis-can-reduce-infections-after-cystectomy-compared-to-empiric-prophylaxis-100570588","NCT06709196","Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.","REINFORCE","Inclusion Criteria:\n\n* Age at surgery ≥ 18 years\n* Ability to understand and sign an informed consent\n* Malignant or benign indication for undergoing cystectomy\n* Planned ileal conduit as urinary diversion\n\nExclusion Criteria:\n\n* Previous severe allergic reaction to antimicrobial treatment\n* Long-term prophylactic antibiotic treatment which is expected to be continued after the cystectomy",{"count":154,"type":20},248,[156],"PHASE4","The aim of this trial is to test whether postoperative antibiotics targeted towards bacteria in the urine can reduce the risk of infection after surgical removal of the bladder (cystectomy) compared to a standardised antibiotic prophylaxis.\n\nParticipants undergoing cystectomy will be randomly assigned to postoperatively receive (A) a standardised orally administered antibiotic prophylaxis currently given at Rigshospitalet, Copenhagen or (B) a conventional orally administered antibiotic prophylaxis targeting bacteria found in the urine postoperatively.\n\nThe investigators' hypothesis is that the targeted prophylactic antibiotic strategy will reduce the number of infection-related readmissions within 90 days of surgery compared to the standardised prophylaxis.",[100,26,159,160,129],"Postoperative Infections","Antibiotic Prophylaxis",[162,163],"Targeted antimicrobial prophylaxis","Infection-related readmissions","2025-01-08",{"date":166,"type":36},"2025-01-09",{"date":168,"type":36},"2025-01-07",{"date":170,"type":20},"2027-01",{"name":172,"class":43},"Rigshospitalet, Denmark"]